OptiNose set terms for its IPO this week, according to a regulatory filing submitted to the SEC.
The company plans to offer 6.3 million shares at $15 – $17 apiece and funds affiliated with Avista Capital Partners intend to buy $25 million worth of shares as part of the offering, according to OptiNose. The company is slated to grant underwriters a 30-day option to buy up to an additional 937,500 shares of common stock at the IPO price.
Get the full story at our sister site, Drug Delivery Business News.